二(2-环氧乙烷基乙基)醚 | 10580-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 中文名称: 二(2-环氧乙烷基乙基)醚
• 英文名称: glycidylmethyl ether
• 英文别名: Bis(3,4-epoxybutyl) ether；2-[2-[2-(oxiran-2-yl)ethoxy]ethyl]oxirane
• CAS: 10580-77-5
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: CMZHETMDWDVBCX-UHFFFAOYSA-N

物化性质

• 沸点：
  223.28°C (rough estimate)
• 密度：
  1.0543 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  34.3
• 氢给体数：
  0
• 氢受体数：
  3

制备方法与用途

类别：有毒物品

• 毒性分级：中毒
• 急性毒性：
  • 口服（大鼠）LD50：1070毫克/公斤
  • 皮肤（兔子）LD50：250毫克/公斤

可燃性危险特性：

• 可燃
• 受热分解，产生刺激性烟雾

储运特性：

• 库房需通风、低温和干燥保存

灭火剂：

• 干粉、泡沫、砂土、二氧化碳或雾状水

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 二(2-环氧乙烷基乙基)醚 在 ammonium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 42.0h， 以9 g的产率得到tert-butyl (2-hydroxy-3-methoxypropyl)carbamate
  参考文献：
  名称：

  [EN] CYCLIC UREA DERIVATIVE
  [FR] DÉRIVÉ D'URÉE CYCLIQUE
  [JA] 環状ウレア誘導体

  摘要：

  这项发明提供了具有DYRK抑制作用的化合物，其由下列一般式（I）表示（式中，A1、A2、L、R1和R2参见说明书）。

  公开号：

  WO2022059778A1

文献信息

• Benzazepine Compound
  申请人：KOSHIO Hiroyuki

  公开号：US20110269744A1

  公开（公告）日：2011-11-03

  [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供的是一种化合物，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。 【解决方案】本发明者研究了具有5-HT 2C 受体激动剂活性的化合物，这种活性有望作为治疗或预防尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等的药物组合物的有效成分。他们发现本发明的苯并环己酮类化合物具有出色的5-HT 2C 受体激动剂活性，从而完成了本发明。换句话说，本发明的苯并环己酮类化合物具有5-HT 2C 受体激动剂活性，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。
• Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes
  申请人：Bannou Tadashi

  公开号：US20050070730A1

  公开（公告）日：2005-03-31

  A silane containing a bulky hydrocarbon group or groups R therein and having the formula (III) R 3-(x+y) (R 1 ) x (R 2 ) y Si(OR 3 ) can be produced by reacting a silane of the formula (I) (R 1 ) x (R 2 ) y SiCl 3-(x+y) (OR 3 ) with a Grignard reagent of the formula (II) RMgX Further, a tri-organo-chlorosilane of the formula (XIIa) (R 1 )(R 2 )(R 3 )SiCl can be produced by reacting a tri-organo-silane of the formula (XIa) (R 1 )(R 2 )(R 3 )SiZ 1 with hydrochloric acid. Furthermore, a tri-organo-monoalkoxysilane of the formula (XXIII) R 3-(x+y) (R 1 ) x (R 2 ) y Si(OR 3 ) can be produced when a silane of the formula (XXI) (R 1 ) x (R 2 ) y SiCl 4-(x+y) is reacted with a Grignard reagent of the formula (XXII) RMgX with addition of and reaction with an alcohol or an epoxy compound during the reaction.

  含有庞大烃基或基团R的硅烷，其具有式(III)R3-(x+y)(R1)x(R2)ySi(OR3)，可通过反应式(I)(R1)x(R2)ySiCl3-(x+y)(OR3)的硅烷与式(II)RMgX的格氏试剂制得。此外，式(XIIa)(R1)(R2)(R3)SiCl的三有机氯硅烷可通过反应式(XIa)(R1)(R2)(R3)SiZ1的三有机硅烷与盐酸制得。再者，当式(XXI)(R1)x(R2)ySiCl4-(x+y)的硅烷与式(XXII)RMgX的格氏试剂反应，并在反应过程中加入并反应酒精或环氧化合物时，可制得式(XXIII)R3-(x+y)(R1)x(R2)ySi(OR3)的三有机单烷氧基硅烷。
• PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES
  申请人：Bannou Tadashi

  公开号：US20090082585A1

  公开（公告）日：2009-03-26

  A silane containing a bulky hydrocarbon group or groups R therein and having the formula (III) R 3−(x+y) (R 1 ) x (R 2 ) y Si(OR 3 ) can be produced by reacting a silane of the formula (I) (R 1 ) x (R 2 ) y SiCl 3−(x+y) (OR 3 ) with a Grignard reagent of the formula (II) RMgX Further, a tri-organo-chlorosilane of the formula (XIIa) (R 1 )(R 2 )(R 3 )SiCl can be produced by reacting a tri-organo-silane of the formula (XIa) (R 1 )(R 2 )(R 3 )SiZ 1 with hydrochloric acid. Furthermore, a tri-organo-monoalkoxysilane of the formula (XXIII) R 3−(x+y) (R 1 ) x (R 2 ) y Si(OR 3 ) can be produced when a silane of the formula (XXI) (R 1 ) x (R 2 ) y SiCl 4−(x+y) is reacted with a Grignard reagent of the formula (XXII) RMgX with addition of and reaction with an alcohol or an epoxy compound during the reaction.

  含有笨重烃基团R的硅烷化合物，其化学式为(III)R3−(x+y)(R1)x(R2)ySi(OR3)，可以通过将化学式为(I)(R1)x(R2)ySiCl3−(x+y)(OR3)的硅烷与化学式为(II)RMgX的格氏试剂反应来制备。此外，可以通过将化学式为(XIa)(R1)(R2)(R3)SiZ1的三元有机硅烷与盐酸反应来制备化学式为(XIIa)(R1)(R2)(R3)SiCl的三元有机氯硅烷。此外，在反应过程中加入醇或环氧化合物，可以通过将化学式为(XXI)(R1)x(R2)ySiCl4−(x+y)的硅烷与化学式为(XXII)RMgX的格氏试剂反应来制备化学式为(XXIII)R3−(x+y)(R1)x(R2)ySi(OR3)的三元有机单烷氧基硅烷。
• BENZAZEPINE COMPOUND
  申请人：Koshio Hiroyuki

  公开号：US20130012496A1

  公开（公告）日：2013-01-10

  Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供了一种化合物，可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。本发明人研究了具有5-HT2C受体激动剂活性的化合物，并发现本发明的苯并氮杂环化合物具有优异的5-HT2C受体激动剂活性，从而完成了本发明。也就是说，本发明的苯并氮杂环化合物具有5-HT2C受体激动剂活性，并可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。
• Dipyridylamine Derivative
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20140073658A1

  公开（公告）日：2014-03-13

  Disclosed herein are compounds, or pharmacologically acceptable salts thereof, having glucokinase activating activity. In various aspects, the compounds are represented by general formula (I), or pharmacologically acceptable salts thereof:

  本文公开了具有葡萄糖激酶激活活性的化合物或其药理学上可接受的盐。在各个方面，这些化合物由一般式（I）或其药理学上可接受的盐所表示：